Contemporary Patterns of Medicare Part B Spending on Immune Checkpoint Inhibitors (2018-2022). (PubMed, JCO Oncol Pract) - Sep 30, 2026 - "Medicare Part B spending on ICIs is highly concentrated among pembrolizumab and nivolumab, and is driven primarily by beneficiary volume, with substantial heterogeneity in per-beneficiary spending across agents. As indications and utilization continue to expand, these therapies' fiscal impact warrants ongoing evaluation to inform Medicare payment policy and value-based oncology care."
Checkpoint inhibition • Journal • Medicare • Reimbursement • US reimbursement • Oncology
|
|
Bradley Switzer; Charmi Bhanushali; Pragya Jain; Sharanya Tripathi; Vidhi Bhanushali; Vidit Majmundar
|